Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit

1 février 2022 mis à jour par: Mikhail Dziadzko, MD, PhD

Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit - a Multicenter Observational Cohort Study

More than six million French were affected by SARS-COV2 epidemic. About 20% of infected peoples were hospitalized, and about 5% were admitted to the intensive care units (ICU) for severe SARS-COV2 acute respiratory distress syndrome (ARDS) management.

A spectrum of neuropsychiatric sequelae, specific for the ICU exposure, was already described, including post-intensive care syndrome and persistent pain.

A growing body of evidence suggests the impact of SARS-COV2 exposure on the occurrence of neurological disorders and chronic pain syndrome development in COVID-19 patients.

Taking together, one can expect a large number of patients discharged from ICU after severe COVID-19 with high prevalence of persistent pain and psychological disorders. To date, no study has evaluated neither the incidence of persistant pains in ICU COVID-19 survivors, nor pain phenotypes.

The knowledge of such data is crucial in order to anticipate the management of such patients by specialized pain team, and to quantify the possible incurred burden of care.

Our study aims to evaluate the incidence of pain, pain localization and severity, associated pain-related psychological disorders, and to perform quantitative sensory testing in severe COVID-19 patients, admitted to the ICU for more than 48 hours and successfully discharged home during the first French pandemic wave.

Aperçu de l'étude

Type d'étude

Observationnel

Inscription (Réel)

143

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Le Kremlin-Bicêtre, France, Le Kremlin-Bicêtre
        • Hôpital Bicêtre AP-HP
      • Lyon, France, 69004
        • Hôpital de la croix Rousse - Hospices Civils de Lyon
    • Hauts-de-Seine
      • Garches, Hauts-de-Seine, France, 92380
        • Hôpital Raymond Poincaré - AP-HP

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

adult patients, infected with SARS COV2 and developed severe COVID, requiring hospitalisation to the ICU during the first French wave of COVID 19, with length of stay > 48 hours, survived and successfully discharged, and approached from 6th month post discharge.

La description

Inclusion Criteria:

  • adults (>=18 y.o.)
  • hospitalized in the ICU for at least 48 hours
  • with SARS-Cov2 infection confirmed by Polymerase Chain Reaction (PCR)/serology and/or a suggestive chest Computed Tomography scan
  • during the first wave of COVID 19 from March to December 2020 at three investigator sites (2 in Paris and 1 in Lyon)
  • discharged alive from the ICU
  • at least 6 months after discharge

Exclusion Criteria:

  • patient refusal
  • inability to communicate or to have in-person appointment
  • death in the period from ICU discharge to the first phone call for interview

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cohorte
  • Perspectives temporelles: Transversale

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
post COVID-19 ICU survivors
Patients hospitalized to the ICU in the context of severe COVID-19 and discharged alive during the first French COVID-19 pandemic wave
Patient-reported outcomes, listed in the Secondary Outcome Measure Section
Summation pain threshold test and Heat pain threshold skin test

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of secondary chronic pain
Délai: starting 6 month after discharge

Secondary chronic pain as defined by International Classification of Disease -11th revision (ICD-11).

Chronic secondary pain is organized into the following six categories:

  1. Chronic cancer-related pain (ICD-11 code MG30.1)
  2. Chronic postsurgical or post-traumatic pain (ICD-11 code MG30.2)
  3. Chronic secondary musculoskeletal pain (ICD-11 code MG30.3)
  4. Chronic secondary visceral pain (ICD-11 code MG30.4)
  5. Chronic neuropathic pain (ICD-11 code MG30.5)
  6. Chronic secondary headache or orofacial pain (ICD-11 code MG30.6)

Any pain detected in the population of interest and fitting in one of 6 categories will be accounted.

starting 6 month after discharge

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Frequency of different secondary chronic pain classes
Délai: starting 6 month after discharge

as defined by ICD-11 and the International Association for the Study of Pain (IASP)

Chronic secondary pain is organized into the following six categories:

  1. Chronic cancer-related pain (ICD-11 code MG30.1)
  2. Chronic postsurgical or post-traumatic pain (ICD-11 code MG30.2)
  3. Chronic secondary musculoskeletal pain (ICD-11 code MG30.3)
  4. Chronic secondary visceral pain (ICD-11 code MG30.4)
  5. Chronic neuropathic pain (ICD-11 code MG30.5)
  6. Chronic secondary headache or orofacial pain (ICD-11 code MG30.6)

For each category of detected pain the frequency will be reported.

starting 6 month after discharge
Pain sensitivity level
Délai: starting 6 month after discharge
Pain sensitivity level is tested with a Pain sensitivity questionnaire (PSQ). PSQ contains 17 items assessing pain with 11 level scoring from 0 (not at all painful) to 10 (most severe pain imaginable). Maximal summation score is 170, higher score mean worse outcome.
starting 6 month after discharge
Pain localization
Délai: starting 6 month after discharge
A Michigan Body Map will be used for pain localization inventory. A Michigan Body Map is a self-report measure to assess body areas where chronic pain is experienced.
starting 6 month after discharge
The severity of pain and its impact on functioning
Délai: starting 6 month after discharge
A Brief Pain Inventory (BPI) will be used to assess the severity of pain and its impact on functioning. The BPI pain scales defines pain as follows: Worst Pain Score: 1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain. BPI Interference Items use 0 (less) to 10 (worth) scoring, the arithmetic mean of the interference items is used as a measure of pain interference, higher score mean worse outcome.
starting 6 month after discharge
Neuropathic pain
Délai: starting 6 month after discharge
A DN4 scale will be used to detect a neuropathic pain. The DN4 (which stands for Douleur Neuropathique 4) is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. Each item has binary value (yes/no), maximal summation score is 10, and the threshold for neuropathic pain is 4.
starting 6 month after discharge
Spiegel Sleep Quality Questionnaire
Délai: starting 6 month after discharge
Spiegel Sleep Questionnaire is a self-rated questionnaire which assesses the current sleep quality and disturbances. It has six 5 point Likert-like items rated from worst to best value. The total summation score is 30, less score values indicates worth outcome. The threshold of bad sleep is less than 15, and the score 20 indicates a good sleep.
starting 6 month after discharge
Posttraumatic Stress Disorder
Délai: starting 6 month after discharge

Posttraumatic Stress Disorder Checklist Scale is a 20-item self-report measure that assesses the symptoms of Posttraumatic Stress Disorder. Respondents rate each item from 0 ("not at all") to 4 ("extremely") to indicate the degree to which they have been bothered by that particular symptom over the past month.

A total symptom severity score is obtained by summing the scores for each of the 20 items. The score superior of 31 is indicative of probable Posttraumatic Stress Disorder.

starting 6 month after discharge
Anxiety and Depression
Délai: starting 6 month after discharge

Hospital Anxiety Depression scale will be used, it measures anxiety and depression in a general medical population of patients. The questionnaire comprises seven questions for anxiety and seven questions for depression. Greater score values indicates worth outcome.

For both scales, scores of less than 7 indicate non-cases; 8-10 - mild depression or anxiety; 11-14 - moderate depression or anxiety; and 15-21 - severe depression or anxiety.

starting 6 month after discharge
Pain Catastrophizing Level
Délai: starting 6 month after discharge
Pain Catastrophizing Scale quantifies an individual's pain experience. It has 13 items rated on 5-point Likert-like scales (0 - not at all to 4 - all the time). A total score is yielded (ranging from 0-52), the threshold above 30 is considered clinically relevant. Higher score indicates higher level of catastrophizing and bad outcome.
starting 6 month after discharge
Perceived Stress Level
Délai: starting 6 month after discharge
Perceived Stress Scale (PSS-10) is a self stress assessment instrument. It has 10 items rated on 5-point Likert-like scales (0 - never to 4 - very often). Individual scores on the PSS-10 can range from 0 to 40 with higher scores indicating higher perceived stress.
starting 6 month after discharge
Summation pain threshold
Délai: starting 6 month after discharge
Mechanical temporal summation will be evoked using methodology described by Weissman-Fogel, 2008, by Von Frey Filaments, using a 180-gr filament that will be applied to the volar aspect of the dominant forearm. Patients will be exposed to a single stimulus and will be asked to rate the level of pinprick pain intensity using 11 items numeric pain scale. This pain score serve as an index for mechanical suprathreshold pain. Subsequently, 1 Hz repetitive stimuli will be applied within an area of 1 cm in diameter, using the same filament, and subjects will be asked to rate the pain intensity of the last stimulus. The magnitude of mechanical temporal summation will be calculated as the difference between the last and the first pain scores. Higher values indicates worth outcome.
starting 6 month after discharge
Heat pain threshold
Délai: starting 6 month after discharge
A heat pain threshold will be realized using Thermal Stimulator for Sensory testing (SOMEDIC(R)). A thermode (heating stick) of 7 square centimeters will be applied to the volar aspect of the dominant forearm. Patients will be exposed to 3 repetitive gradual increase in temperature from 32° to 52°C. The skin contact will be withdrawn if an individual is not able to tolerate such stimulation, and the temperature threshold of tolerance will be noted. The final reading will be the median of three measurements, higher values indicate better tolerance.
starting 6 month after discharge

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

11 janvier 2021

Achèvement primaire (Réel)

1 janvier 2022

Achèvement de l'étude (Réel)

1 février 2022

Dates d'inscription aux études

Première soumission

21 juin 2021

Première soumission répondant aux critères de contrôle qualité

23 juin 2021

Première publication (Réel)

25 juin 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 février 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

1 février 2022

Dernière vérification

1 février 2022

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

Non

Description du régime IPD

individual participant data are the property of investigator's centers and will not be shared

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner